drugset
drugset / Trial / NCT02978339

A Study Evaluating the Safety and Efficacy of Curcumin in Patients With Primary Sclerosing Cholangitis (PSC)

NCT02978339 ↗

Phase 1/2 Completed 15 enrolled John E. Eaton EuroPharma, Inc. · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether curcumin, a drug and naturally-occurring plant compound, is safe and effective in the treatment of primary sclerosing cholangitis (PSC).

Timeline

Start
2017-06-09
Primary completion
2018-11-16
Completion
2019-01-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Curcumin Small molecule 500 mg Oral

Indications

primary sclerosing cholangitis